Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Carcinoma, Renal Cell
Intervention: Sorafenib (Nexavar, BAY43-9006) (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s): Bayer Study Director, Study Director, Affiliation: Bayer
Summary
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate
the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Clinical Details
Official title: Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
Secondary outcome: Overall tolerability of treatment as measured by rate of adverse events
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age >/= 18 years
- Diagnosis of renal cell carcinoma
- Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or
disqualified from therapy with IFN/IL-2
- Patients in whom the oncologist has decide to start therapy with sorafenib.
Exclusion Criteria:
- Synonymous with contraindications to Nexavar.
Locations and Contacts
Many Locations, Poland
Additional Information
Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: February 2010
Last updated: June 17, 2015
|